• GANT61 in ALK-Positive ALCL: Cell-Cycle Evidence

  2026-10-05

  A 2026 Annals of Hematology study links GANT61-mediated Gli1 inhibition with reduced proliferation, cell-cycle arrest, apoptosis, and modulation of the PIK3IP1-Akt axis in ALK-positive anaplastic large cell lymphoma. The findings support a mechanistic model for further investigation, while remaining limited by their predominantly cellular and correlative evidence base.

• DFO Fingerprint Detection: Evidence and Limits

  2026-10-05

  DFO, or 9H-1,8-Diazafluoren-9-one, is described by APExBIO as a fluorescent reagent for amino-acid-based latent fingerprint visualization on porous materials. This overview separates supplier claims from published evidence, outlines appropriate forensic research questions, and explains why a silver-nanoparticle ferroptosis study does not validate DFO performance or safety.

• Pyridostigmine, α7 Signaling, and Placental Necroptosis

  2026-10-04

  A 2026 study connects placental ischemia, necroptosis, and non-neuronal cholinergic signaling in a rat model of preeclampsia-like disease. Its antagonist and inhibitor comparisons suggest that α7 nicotinic acetylcholine receptor activity contributes to pyridostigmine-associated reductions in placental injury, inflammation, and maternal hypertension, while leaving important questions about causality and translation unresolved.

• IR-1061: Translating NIR-II Imaging Beyond Brightness

  2026-10-03

  IR-1061 illustrates why translational NIR-II imaging depends on more than emission intensity. This thought-leadership perspective connects aggregation state, carrier architecture, biological targeting, and evidence standards while distinguishing reported findings from future research opportunities.

• PEDV Hijacks IMPDH-Dependent Nucleotide Biosynthesis

  2026-10-02

  A recent reference study shows that porcine epidemic diarrhea virus (PEDV) reprograms host purine metabolism and depends on IMPDH2-driven guanine nucleotide biosynthesis for efficient replication. By combining untargeted metabolomics, IMPDH2 knockdown, and Merimepodib (VX-497) treatment, the work identifies IMPDH as a host-directed antiviral vulnerability while highlighting strong cell-context effects.

• Entinostat: Separating Growth Arrest from Cell Death

  2026-10-01

  Entinostat and MS-275 are selective class I HDAC inhibitors with value beyond simple viability screening. This guide explains how to distinguish epigenetic growth arrest from true cancer-cell killing and design more informative translational assays.

• Z-WEHD-FMK in Caspase-1 Pyroptosis Assays

  2026-10-01

  Z-WEHD-FMK is a cell-permeable, irreversible inhibitor for interrogating inflammatory caspase activity. This article explains how to use it to distinguish caspase expression, protease activity, pyroptosis, and pathogen-driven organelle remodeling in advanced cell-based assays.

• Merimepodib (VX-497): IMPDH Assay Strategy

  2026-09-30

  Merimepodib (VX-497) offers a precise way to interrogate IMPDH-dependent guanine nucleotide metabolism. This article translates recent PEDV findings into assay-design decisions that distinguish antiviral activity, cytostasis, and target-specific nucleotide depletion.

• Targeted mRNA Nanoparticles Repair the Poststroke BBB

  2026-09-30

  The ACS Nano study developed mannose-targeted lipid nanoparticles carrying IL-10 mRNA to redirect microglia toward an anti-inflammatory state after ischemic stroke. In mouse models, this strategy reduced neuroinflammation, improved blood–brain barrier integrity, limited neuronal apoptosis, and preserved neurological function, while suggesting a therapeutic window extending to at least 72 hours.

• nor-NOHA Acetate Research Workflows

  2026-09-29

  Build reversible arginase-perturbation experiments around nor-NOHA acetate, from HepG2 apoptosis and invasion assays to endothelial signaling studies. A carefully bounded AML extension uses the compound as an arginine-metabolism probe alongside the CD36 lipid-immune framework, not as a validated AML treatment.

• EZ Cap™ Mouse CD252(OX40L) mRNA: Assay Logic

  2026-09-29

  EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) enables controlled OX40L co-stimulation studies. This guide focuses on causal assay design and explains how to interpret related CD80 and 4-1BBL mRNA vaccine evidence without overextending its conclusions.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-09-28

  This study identifies MDM1 as a regulator of TP53 expression and apoptosis that influences colorectal cancer sensitivity to chemoradiotherapy. Its combination of genetic perturbation, transcriptomic analysis, promoter studies, and in vivo validation supports MDM1 as a candidate predictive biomarker and highlights apoptosis modulation as a strategy for investigating treatment resistance.

• CFTRinh-172: Selective CFTR Channel Inhibition

  2026-09-28

  CFTRinh-172 is a reversible CFTR inhibitor used to study cAMP-activated chloride transport in epithelial models. Product information reports rapid in vitro inhibition and reduced cholera toxin-induced intestinal fluid secretion in mice, but the compound is a research tool—not a treatment for cystic fibrosis or diarrhea.

• Merimepodib and the Translational Logic of IMPDH

  2026-09-27

  Merimepodib (VX-497) offers a way to interrogate a central metabolic dependency: guanine nucleotide synthesis. Recent PEDV findings support IMPDH as a host factor for viral replication, while also underscoring why cell context, orthogonal validation, and careful translational boundaries matter.

• Exemestane Workflows for Aromatase Research

  2026-09-26

  Build reproducible aromatase studies around Exemestane’s irreversible, steroidal mechanism—from enzyme assays to estrogen readouts in breast cancer research. A practical pilot workflow covers dose selection, vehicle matching, washout design, and common assay failures without treating a reported IC50 as a universal cellular dose.

8536 records 1/570 page Next 12345 下5页 Last page